Author details

Full Name

Ayman Tourbah

Affiliation

ORCID

Career Start Year

1988

Papers

127

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
33989458	Social cognition and executive functioning in multiple sclerosis: A cluster-analytic approach.	Journal of Neuropsychology	2022
36180289	Secondary progressive multiple sclerosis: A national consensus paper on diagnostic criteria.	Revue Neurologique	2022
35378396	Health related quality of life and perceived social support in French and Lebanese MS patients: A comparative study.	Multiple Sclerosis and Related Disorders	2022
34633424	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome.	JAMA network open	2021
33903203	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.	Neurology: Neuroimmunology and NeuroInflammation	2021
34352512	MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis.	Multiple Sclerosis and Related Disorders	2021
33103295	Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders.	European Journal of Neurology	2021
31479149	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.	JAMA Neurology	2020
32862037	Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.	Multiple Sclerosis and Related Disorders	2020
32629363	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.	Mult Scler Relat Disord	2020
31538396	MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests.	European Journal of Neurology	2020
31148523	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.	Multiple Sclerosis Journal	2020
31300547	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.	Neurology	2019
31563076	Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis.	Multiple Sclerosis and Related Disorders	2019
30317070	Anxiety and depression in patients with multiple sclerosis: The mediating effects of perceived social support.	Multiple Sclerosis and Related Disorders	2019
29808469	MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.	CNS Drugs	2018
28337934	Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?	Multiple Sclerosis Journal	2018
30175630	Co-occurrence of MS and ALS: a clue in favor of common pathophysiological findings?	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration	2018
29695592	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.	Neurology	2018
29414300	Letter to the Editors - Multiple sclerosis and related disorders - Birnbaum et al., 2017.	Multiple Sclerosis and Related Disorders	2018
29064775	USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up.	Mult Scler	2018
27899553	Reply to Letter to the Editor: Biotin supplementation in MS clinically valuable but can alter multiple blood test results by Siddiqui U, et al.	Multiple Sclerosis Journal	2017
28681388	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.	Ann Neurol	2017
28616447	Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.	Neurology: Neuroimmunology and NeuroInflammation	2017
28656885	Social Cognition Abilities in Patients With Different Multiple Sclerosis Subtypes.	Journal of the International Neuropsychological Society	2017
29141801	Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?	Multiple Sclerosis and Related Disorders	2017
29111024	Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year.	Journal of the Neurological Sciences	2017
27959267	Theoretical modeling of time-dependent skin temperature and heat losses during whole-body cryotherapy: A pilot study.	Medical Hypotheses	2016
30512397	[Which prognostic criteria in multiple sclerosis?]		2016
27000224	Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.	Journal of the Neurological Sciences	2016
26826205	Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.	Neurology	2016
26984608	Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat.	Journal of Neurology	2016
26453679	Ultra-small superparamagnetic iron oxide enhancement is associated with higher loss of brain tissue structure in clinically isolated syndrome.	Mult Scler	2016
26327679	Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis.	Neuropharmacology	2016
27589059	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.	Multiple Sclerosis Journal	2016
27815407	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.	Neurology	2016
26292991	The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study.	Annals of Neurology	2015
25787192	High doses of biotin in chronic progressive multiple sclerosis: a pilot study.	Multiple Sclerosis and Related Disorders	2015
25683762	Criteria improving multiple sclerosis diagnosis at the first MRI.	Journal of Neurology	2015
26227004	Biotin and demyelinating diseases--a new connection?	Multiple Sclerosis Journal	2015
24687771	Brain networks disconnection in early multiple sclerosis cognitive deficits: an anatomofunctional study.	Human Brain Mapping	2014
23895407	A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.	European Journal of Neurology	2014
24139244	[Progressive multifocal leukoencephalopathy and natalizumab-related immune reconstitution inflammatory syndrome: the advantage of MRI].	Revue Neurologique	2014
23830586	POLG mutations associated with remitting/relapsing neurological events.	Journal of Clinical Neuroscience	2014
24493555	Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.	Annals of Neurology	2014
24726435	[Chronic meningoencephalitis with dementia].	Revue Neurologique	2014
24726436	Progressive neuropsychiatric manifestations of phenylketonuria in adulthood.	Revue Neurologique	2014
25215443	Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.	Clinical Neurology and Neurosurgery	2014
24566807	Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.	JAMA Neurology	2014
24924476	[Eight and a half plus syndrome as a first presentation of multiple sclerosis].	Revue Neurologique	2014